Once the court approves the agreement, non-adherent creditors will face a 75% reduction in their outstanding balance. The remaining debt will accrue interest based on the TR , currently estimated at 0 ...
Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination product candidate for the treatment of Parkinson’s Disease (“PD”) and Hepion ...
Ark Invest CEO Cathie Wood said key technologies such as AI and digital assets would be drivers of explosive growth in the ...